European Association of Dermato-Oncology 16th European Post-Chicago Melanoma Skin Cancer Meeting 2026

European Association of Dermato-Oncology 16th European Post-Chicago Melanoma Skin Cancer Meeting 2026

+ Target Audience: dermatologists, oncologists, surgeons, and other healthcare professionals

+ Information:

The 16th European Post-Chicago Melanoma/Skin Cancer Meeting (EPCM) will be held from June 25th-26th, 2026, at the Radisson Blu Hotel in Hamburg, Germany. Organized under the auspices of the Melanoma World Society (MWS) and the European Association of Dermato Oncology (EADO), this interdisciplinary global conference aims to present emerging developments in melanoma and skin cancer diagnostics and therapy. The program features international key opinion leaders sharing their latest research, clinical trial results, and insights from the recent ASCO meeting.

Learning Objectives

After completing this activity, participants should be better able to:

• Evaluate the latest highlights from ASCO 2026 regarding melanoma and non-melanoma skin cancer.

• Understand the role of dermoscopy in detecting all types of skin cancers.

• Assess how lifestyle factors, such as exercise, nutrition, and timing of ICI administration, impact cancer treatment outcomes.

• Review updates from various melanoma registries and databases across Europe.

• Manage treatments for vulnerable skin cancer populations, including frail, immunocompromised, and family-planning patients.

• Apply gene expression profiling (GEP) in melanoma management and interpret the 2026 EADO guidelines for basal cell and cutaneous squamous cell carcinomas.

• Evaluate the role of ImmTACs (bi-specific agents) for metastatic uveal and cutaneous melanomas, and discuss the management of melanoma brain metastases.

• Assess the existence of the abscopal effect of radiotherapy and current strategies for adjuvant and neoadjuvant melanoma treatments.

Target Audience

• This educational activity is intended for dermatologists, oncologists, surgeons, and other healthcare professionals involved in the diagnosis, treatment, and research of melanoma and non-melanoma skin cancers.
• Best for Dermatologists, Medical Oncologists, Surgical Oncologists, and Radiation Oncologists.

Topics

• SYMPOSIUM I: My personal highlights at ASCO 2026

  • in melanoma

  • in non-melanoma skin cancer

• KEYNOTE LECTURE I: Dermoscopy for the detection of all skin cancers?!

• SYMPOSIUM II: Lifestyle factors impacting cancer treatment outcomes

  • Exercise

  • Nutrition

  • Timing of ICI administration

• SYMPOSIUM III: Merkel Cell Carcinoma

  • Adjuvant and neoadjuvant trials

  • Role of irradiation for MCC

  • Treatment for advanced MCC

• SYMPOSIUM IV: Treatment of vulnerable skin cancer patients

  • Family planning

  • Old and frail patients

  • Immunocompromised patients

• SYMPOSIUM V: Adverse event management for ICI

  • Long-term toxicities / delayed onset toxicities

  • ICI rechallenge after immune-related adverse events

  • What you should know about differences of various immunosuppressants

• SYMPOSIUM VI: GEP – Gene expression profiling

  • Which test is the best for melanoma?

  • What can we learn from Breast Cancer (Oncotype DX Test)?

  • How to implement GEP in melanoma guidelines?

• SYMPOSIUM VII: EADO guidelines 2026 for various skin cancers: What’s new?

  • …basal cell carcinoma (BCC)

  • …cutaneous squamous cell carcinoma (CSCC)

  • …current trials for BCC/CSCC with future implications

• SYMPOSIUM VIII: ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas

  • Treatment of metastatic ocular melanoma: it’s a whole new world!

  • Tebentafusp, Brenetafusp and other ImmTACs not only for uveal melanoma

• KEYNOTE LECTURE II: Personalized oncology: already reality or just a dream?

• KEYNOTE LECTURE III: Neoadjuvant or perioperative treatment for melanoma?

• SYMPOSIUM IX: Is the abscopal effect of radiotherapy existing? (Yes / No Panel Discussion)

• SYMPOSIUM X: Adjuvant treatment of melanoma

  • Targeted therapy or immune checkpoint inhibition for BRAF mutated stage III patients?

  • Is combo immune checkpoint inhibition replacing single agent anti-PD1?

  • How long is long enough?

• Satellite Symposia:

  • Nuances in Metastatic Uveal Melanoma Care A Global Dialogue on current Clinical Practice, Treatment Algorithms and Emerging Insights

  • Advancing Treatment Pathways in Cutaneous Squamous Cell Carcinoma: Patients to Practice

  • Early-Stage Melanoma in Daily Practice: Are We Ready for Individualized Therapy?

  • Redefining Melanoma Care 2026: Innovation, Evidence, Outcomes

  • Immune checkpoint inhibitors in Merkel cell carcinoma: 10 years of progress from 2016 to 2026